Leadership Transition Overshadows Legal Victory for BioNTech

BioNTech secures major court win against Poland & Romania for unpaid COVID-19 doses, while restructuring leadership and pivoting focus to oncology.

A significant legal win in Brussels this week has been somewhat eclipsed by internal changes at BioNTech SE. The biotech firm, alongside its partner Pfizer, secured a favorable court ruling against Poland and Romania concerning unpaid COVID-19 vaccine contracts. This financial boost arrives as the company undertakes a major overhaul of its executive leadership and continues its strategic pivot toward oncology.

Financial Windfall from Vaccine Contract Dispute

On April 1, a Brussels court ordered Poland to pay €1.3 billion and Romania €600 million for doses of the Comirnaty vaccine they had ordered but subsequently refused to accept. Pfizer had initiated legal proceedings against both nations in 2023, citing persistent breach of contract.

The court dismissed the defenses presented by the two governments. Arguments regarding alleged unfair contract terms or a fundamental change in circumstances during the pandemic were not accepted as valid grounds for termination. Poland has stated its intention to pursue all available legal appeals. Meanwhile, Romania's health minister openly acknowledged that the ministry currently lacks the funds and would need to draw from the state budget.

The enforceability of these judgments remains uncertain. Furthermore, a similar case against Hungary is scheduled for April 16, where Pfizer is seeking approximately €60 million plus interest.

Concurrent Restructuring at the Top

Preparations are underway for BioNTech's virtual Annual General Meeting on May 15, 2026. Shareholders will be asked to vote on several key items, including a proposal to expand the Supervisory Board from six to eight members. The board has nominated Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich as new candidates, both of whom bring extensive expertise in oncology and clinical development.

The agenda also features a proposal for new authorized capital 2026 of up to approximately €129.5 million, equivalent to 50% of the current share capital. Additionally, the entire retained profit for 2025, amounting to roughly €6.9 billion, is to be carried forward, with no dividend distribution planned.

Robust Liquidity Amid Declining Revenue

BioNTech's financial picture presents a dichotomy. The company reported a net loss of €1.14 billion for 2025 on revenues of €2.87 billion. Management forecasts revenues for 2026 to be in the range of €2.0 to €2.3 billion, indicating a further year-on-year decline.

Despite this, BioNTech maintains a formidable cash position, with liquidity reserves of about €17.2 billion to fund its ongoing transformation. Founders CEO Ugur Sahin and CMO Özlem Türeci are set to depart the company by the end of 2026 to establish a new mRNA-focused venture. The search for their successors is currently in progress.

Strategic Focus Shifts to Oncology Pipeline

The core of BioNTech's new strategic direction is its oncology pipeline. The company aims to have 15 ongoing Phase 3 trials in cancer research by the end of this year. A key program under watch is the PRESERVE-003 trial for the anti-CTLA-4 antibody candidate, gotistobart, in squamous non-small cell lung cancer. Data from this trial was recently presented at the European Lung Cancer Congress in Copenhagen. However, the company's management does not anticipate commercial revenue from this pipeline before 2026.